ArticleJournal for immunotherapy of cancer2026
Tumor-derived HMGB2 induces M2-like macrophage polarization via TRIM65-mediated NLRP3 degradation to promote DLBCL progression.
Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma. Although standard immunochemotherapy is available, 30%-40% of patients develop refractory or relapsed disease, underscoring the need to elucidate the underlying mechanisms of therapy resistance. High mobility group box 2 (HMGB2) is overexpressed in DLBCL; however, its role in the pathogenesis of DLBCL and in mediating therapy resistance remains unclear.
methodsHMGB2 expression and prognostic value in DLBCL were analyzed using public databases, validated by quantitative reverse transcription-PCR and western blot analysis. In vivo and in vitro HMGB2 knockdown models were constructed to explore its role in DLBCL. Macrophage-DLBCL co-culture systems were established to investigate HMGB2-mediated macrophage polarization. Transcriptome sequencing was performed to identify downstream targets of HMGB2, with molecular mechanisms confirmed by western blot analysis, co-immunoprecipitation, and immunofluorescence. Exosome isolation and protease protection assays were used to determine the HMGB2 secretion pathway.
resultsHMGB2 is overexpressed in DLBCL and correlates with poor prognosis. While HMGB2 knockdown showed no cell-intrinsic effects in vitro, it significantly suppressed tumor progression in vivo by remodeling the tumor microenvironment. We identified a novel mechanism whereby exosomal HMGB2 derived from DLBCL cells upregulates the E3 ubiquitin ligase tripartite motif containing 65 (TRIM65) in macrophages, promoting ubiquitin-mediated degradation of the NOD-like receptor protein 3 (NLRP3) inflammasome. This cascade drives M2-like macrophage polarization and impairs phagocytic function. Therapeutic targeting of this axis restored macrophage phagocytosis and synergized with CD20 immunotherapy to enhance its antitumor efficacy.
conclusionOur study defines the HMGB2-TRIM65-NLRP3 axis as a pivotal immunosuppressive pathway in DLBCL. Targeting this axis represents a promising combinatory strategy to reprogram the tumor microenvironment and overcome therapy resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.